Literature DB >> 27432471

Quantitative proteomics identifies myoferlin as a novel regulator of A Disintegrin and Metalloproteinase 12 in HeLa cells.

Yanqing Zhou1, Lipeng Xiong1, Yang Zhang1, Rong Yu2, Xiaogang Jiang1, Guoqiang Xu3.   

Abstract

UNLABELLED: A Disintegrin and Metalloproteinase 12 (ADAM12) is expressed significantly higher in multiple tumors than in normal tissues and has been used as a prognostic marker for the evaluation of cancer progression. Although several ADAM12 substrates have been identified biochemically and its proteolytic function has been explored, the upstream regulators and the interacting proteins have not been systematically investigated. Here, we use immunoprecipitation and mass spectrometry (MS)-based quantitative proteomic approaches to identify 28 interacting partners for the long form of ADAM12 (ADAM12-L) in HeLa cells. Proteins that regulate cell proliferation, invasion, and epithelial to mesenchymal transition are among the identified ADAM12-interacting proteins. Further biochemical experiments discover that the protein level and the stability of ADAM12 are upregulated by one of its interacting proteins, myoferlin. In addition, myoferlin also increases the proteolytic activity of ADAM12, leading to the reduction of an ADAM12 substrate, E-cadherin. This result implies that ADAM12 and its interacting proteins might converge to certain signaling pathways in the regulation of cancer cell progression. The information obtained here might be useful in the development of new strategies for modulating cell proliferation and invasion involved in the regulation between ADAM12 and its interacting partners. MS data are available via ProteomeXchange with identifier PXD003560. BIOLOGICAL SIGNIFICANCE: Regulation of the proliferation and invasion of cancer cells is important in cancer treatment. ADAM12 has been found to play important roles in regulating these processes and identification of its interacting partners will improve our understanding of its biological functions and provide basis for functional modulation. Through mass spectrometry-based quantitative proteomic approaches, we identify the interacting partners for ADAM12 in a human cancer cell line and find many proteins that are involved in the proliferation and invasion of cancer cells. A novel regulator, myoferlin, of ADAM12 is discovered and this protein increases ADAM12 expression level, stability, and its enzymatic activity, leading to the reduction of its substrate, E-cadherin, which plays important roles in the regulation of cell adhesion and tumor metastasis. This result provides a connection for two highly expressed proteins in cancer cells and may shed light on the regulation of their biological functions in cancer progression.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADAM12; E-cadherin; Label-free; Myoferlin; Quantitative proteomics; Spectral counting

Mesh:

Substances:

Year:  2016        PMID: 27432471     DOI: 10.1016/j.jprot.2016.07.015

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  11 in total

1.  Ubiquitin-conjugating enzyme UBE2O regulates cellular clock function by promoting the degradation of the transcription factor BMAL1.

Authors:  Suping Chen; Jing Yang; Yang Zhang; Chunyan Duan; Qing Liu; Zhengyun Huang; Ying Xu; Liang Zhou; Guoqiang Xu
Journal:  J Biol Chem       Date:  2018-06-05       Impact factor: 5.157

2.  A-44G transition in SMN2 intron 6 protects patients with spinal muscular atrophy.

Authors:  Xingxing Wu; Shu-Huei Wang; Junjie Sun; Adrian R Krainer; Yimin Hua; Thomas W Prior
Journal:  Hum Mol Genet       Date:  2017-07-15       Impact factor: 6.150

3.  Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.

Authors:  Madhuri Jayathirtha; Anca-Narcisa Neagu; Danielle Whitham; Shelby Alwine; Costel C Darie
Journal:  Am J Cancer Res       Date:  2022-04-15       Impact factor: 5.942

4.  Cereblon suppresses the lipopolysaccharide-induced inflammatory response by promoting the ubiquitination and degradation of c-Jun.

Authors:  Jing Yang; Min Huang; Liang Zhou; Xian He; Xiaogang Jiang; Yang Zhang; Guoqiang Xu
Journal:  J Biol Chem       Date:  2018-05-10       Impact factor: 5.157

5.  The E3 ubiquitin ligase STUB1 attenuates cell senescence by promoting the ubiquitination and degradation of the core circadian regulator BMAL1.

Authors:  Kifayat Ullah; Suping Chen; Jiaqi Lu; Xiaohui Wang; Qing Liu; Yang Zhang; Yaqiu Long; Zhanhong Hu; Guoqiang Xu
Journal:  J Biol Chem       Date:  2020-02-10       Impact factor: 5.157

6.  Down-regulating Myoferlin inhibits the vasculogenic mimicry of melanoma via decreasing MMP-2 and inducing mesenchymal-to-epithelial transition.

Authors:  Wenxue Zhang; Ping Zhou; Ai Meng; Rongxin Zhang; Yan Zhou
Journal:  J Cell Mol Med       Date:  2017-11-22       Impact factor: 5.310

7.  Ubiquitin specific peptidase 5 regulates colorectal cancer cell growth by stabilizing Tu translation elongation factor.

Authors:  Xin Xu; Aiwen Huang; Ximao Cui; Kunkun Han; Xiaodan Hou; Qun Wang; Long Cui; Yili Yang
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

Review 8.  Ferlin Overview: From Membrane to Cancer Biology.

Authors:  Olivier Peulen; Gilles Rademaker; Sandy Anania; Andrei Turtoi; Akeila Bellahcène; Vincent Castronovo
Journal:  Cells       Date:  2019-08-22       Impact factor: 6.600

Review 9.  Myoferlin, a Membrane Protein with Emerging Oncogenic Roles.

Authors:  Yimin Dong; Honglei Kang; Huiyong Liu; Jia Wang; Qian Guo; Chao Song; Yunlong Sun; Ya Zhang; Honghua Zhang; Zheng Zhang; Hanfeng Guan; Zhong Fang; Feng Li
Journal:  Biomed Res Int       Date:  2019-11-19       Impact factor: 3.411

Review 10.  Proteomic Technology "Lens" for Epithelial-Mesenchymal Transition Process Identification in Oncology.

Authors:  Monica Neagu; Carolina Constantin; Marinela Bostan; Constantin Caruntu; Simona Rebeca Ignat; Sorina Dinescu; Marieta Costache
Journal:  Anal Cell Pathol (Amst)       Date:  2019-10-29       Impact factor: 2.916

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.